KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Equity Income (2019 - 2022)

Biogen has reported Equity Income over the past 8 years, most recently at $3.4 million for Q3 2022.

  • For Q3 2022, Equity Income fell 92.44% year-over-year to $3.4 million; the TTM value through Jun 2023 reached $3.4 million, down 97.42%, while the annual FY2022 figure was $2.6 million, 92.55% down from the prior year.
  • Equity Income for Q3 2022 was $3.4 million at Biogen, down from $45.0 million in the prior quarter.
  • Over five years, Equity Income peaked at $45.0 million in Q2 2021 and troughed at -$28.7 million in Q1 2019.
  • A 4-year average of $15.7 million and a median of $25.9 million in 2019 define the central range for Equity Income.
  • Biggest five-year swings in Equity Income: soared 307.36% in 2020 and later tumbled 92.44% in 2022.
  • Year by year, Equity Income stood at $33.8 million in 2019, then tumbled by 46.75% to $18.0 million in 2020, then soared by 150.0% to $45.0 million in 2021, then tumbled by 92.44% to $3.4 million in 2022.
  • Business Quant data shows Equity Income for BIIB at $3.4 million in Q3 2022, $45.0 million in Q2 2022, and -$3.3 million in Q1 2022.